Emerging therapies for patients with advanced chronic lymphocytic leukaemia

Blood Reviews

Volumn 23, Issue 5, 2009, Pages 217-224

  Delgado, Julio ^a   Briones, Javier ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

17p Deletion; Chronic lymphocytic leukaemia; Fludarabine refractory; Monoclonal antibodies; Purine analogues

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; FLAVOPIRIDOL; FLUDARABINE; GA 101; GLUCOCORTICOID; GX 10 070; LENALIDOMIDE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OBATOCLAX; OFATUMUMAB; OXALIPLATIN; PENTOSTATIN; RITUXIMAB; ROMIDEPSIN; ROSCOVITINE; THALIDOMIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOMA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FLAVONOIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PIPERIDINES;

EID: 68349135278     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.07.001     Document Type: Article

References (90)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer statistics review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site; 2008.
3. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., and Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
4. Binet J.L., Leporrier M., Dighiero G., et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 40 (1977) 855-864
5. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood 111 (2008) 5446-5456
6. Moreno C., and Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 22 (2008) 211-219
7. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 (2007) 799-804
8. Catovsky D., Richards S., Matutes E., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (2007) 230-239
9. Stilgenbauer S, Zenz T, Winkler D et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab in the CLL8 Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 781.
10. Dighiero G., Maloum K., Desablens B., et al. Chlorambucil in indolent chronic lymphocytic leukemia. French cooperative group on chronic lymphocytic leukemia. N Engl J Med 338 (1998) 1506-1514
11. Nabhan C., Shanafelt T.D., and Kay N.E. Controversies in the front-line management of chronic lymphocytic leukemia. Leukemia Res 32 (2008) 679-688
12. Eichhorst B., Goede V., and Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leukemia Lymphoma 52 (2009) 171-178
13. Eichhorst BF, Busch R, Stauch M et al. No significant clinical benefit of first line therapy with fludarabine in comparison to chlorambucil in elderly patients with advanced chronic lymphocytic leukemia: Results of a phase III study of the German CLL Study Group [abstract]. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 629.
14. Flinn I.W., Neuberg D.S., Grever M.R., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 25 (2007) 793-798
15. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
16. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 (2005) 49-53
17. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112 (2008) 975-980
18. Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol, in press.
19. Hallek M, Fingerle-Rowson G, Fink A-M et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab versus fludarabine and cyclophosphamide improves response rates and progression-free survival in previously untreated patients with advanced chronic lymphocytic leukaemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 325.
20. Kay N.E., Geyer S.M., Call T.G., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2007) 405-411
21. Lamanna N., Jurcic J.G., Noy A., et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 27 (2009) 491-497
22. Foon K.A., Boyiadzis M., Land S.R., et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27 (2009) 498-503
23. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
24. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25 (2007) 5616-5623
25. Bosch F., Ferrer A., Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 14 (2008) 155-161
26. Wierda W., O'Brien S., Faderl S., et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106 (2006) 337-345
27. Bosch F., Ferrer A., López-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119 (2002) 976-984
28. Robak T, Moiseev SI, Dmoszynska A et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival in relapsed or refractory chronic lymphocytic leukaemia compared with FC alone: Final results from the International Randomized Phase III REACH Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract lba-1.
29. Lamanna N., Kalaycio M., Maslak P., et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 1575-1581
30. Elter T., Borchmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031
31. Weiss M.A., Maslak P.G., Jurcic J.G., et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21 (2003) 1278-1284
32. Montillo M., Tedeschi A., O'Brien S., et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97 (2003) 114-120
33. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
34. Karlsson C., Lundin J., Kimby E., et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 144 (2009) 78-85
35. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4070-4078
36. Gribben J.G. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 15 Suppl. 1 (2009) 53-58
37. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21 (2007) 12-17
38. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 (2005) 1029-1033
39. Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., and Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111 (2008) 446-452
40. Hoogendoorn M., Jedema I., Barge R.M., et al. Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning. Leukemia 21 (2007) 2569-2574
41. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British society of blood and marrow transplantation study. Blood 107 (2006) 1724-1730
42. Ritgen M., Böttcher S., Stilgenbauer S., et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22 (2008) 1377-1386
43. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26 (2008) 4912-4920
44. Delgado J., Pillai S., Benjamin R., et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 14 (2008) 1288-1297
45. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukaemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 11 (2005) 7757-7763
46. Schetelig J., van Biezen A., Brand R., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European group for blood and marrow transplantation analysis. J Clin Oncol 26 (2008) 5094-5100
47. Keating M.J., Kantarjian H., O'Brien S., et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9 (1991) 44-49
48. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347 (1996) 1432-1438
49. Keating M.J., O'Brien S.O., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia Lymphoma 34 (2002) 1755-1762
50. Perkins J.G., Flynn J.M., Howard R.S., and Byrd J.C. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Implications for clinical trials in this patient population. Cancer 94 (2002) 2033-2039
51. Döhner H., Fischer K., Bentz M., et al. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995) 1580-1589
52. Gribben J.G., and Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 144 (2009) 818-831
53. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
54. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;doi:10.1200/JCO.2008.21.1128.
55. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
56. Tam C.S., O'Brien S., Lerner S., et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leukemia Lymphoma 48 (2007) 1931-1939
57. Huhn D., von Schilling C., Wilhelm M., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98 (2001) 1326-1331
58. Teeling J.L., French R.R., Cragg M.S., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (2004) 1793-1800
59. Coiffier B., Lepretre S., Pedersen L.M., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111 (2008) 1094-1100
60. Osterborg A, Kipps T, Mayer J et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an International Pivotal Trial [abstract]. Blood (ASH Annual Meeting Abstract) 2008;112: Abstract 328.
61. Fries T, Gerdes C, Nopora A et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, mediates superior efficacy in a variety of NHL xenograft models in comparison to rituximab [abstract]. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 2338.
62. Byrd J.C., O'Brien S., Flinn I.W., et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 13 (2007) 4448-4455
63. Byrd JC, Castro J, O'Brien S et al. Comparison of results from a phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results [abstract]. Blood (ASH Annual Meeting Abstracts) 2006;108: Abstract 32.
64. Tsimberidou A.M., Wierda W.G., Plunkett W., et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26 (2008) 196-203
65. Castro J.E., Sandoval-Sus J.D., Bole J., Rassenti L., and Kipps T.J. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22 (2008) 2048-2053
66. Dungarwalla M., Evans S.O., Riley U., Catovsky D., Dearden C.E., and Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 93 (2008) 475-476
67. Wierda W, O'Brien S, Faderl S et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract]. Blood (ASH Annual Meeting Abstracts) 2006;108: Abstract 31.
68. Wierda W, O'Brien S, Faderl S et al. CFAR, an active frontline regimen for high-risk patients with CLL, including those with del17p [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 2095.
69. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab for patients with relapsed chronic lymphocytic leukemia: a multicentre phase II trial of the German CLL Study Group [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 330.
70. Chanan-Khan A., Miller K.C., Takeshita K., et al. Results of a phase I clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia. Blood 106 (2005) 3348-3352
71. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 5343-5349
72. Andritsos L.A., Johnson A.J., Lozanski G., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26 (2008) 2519-2525
73. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111 (2008) 5291-5297
74. Ferrajoli A, Keating M, Wierda W et al. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia carrying unfavorable chromosomal abnormalities [abstract]. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 754.
75. Chanan-Khan A, Czuczman M, Padmanabhan S et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 3108.
76. Byrd J.C., Shinn C., Waselenko J.K., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92 (1998) 3804-3816
77. Flinn I.W., Byrd J.C., Bartlett N., et al. Flavopiridol administered as a 24-h continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Res 29 (2005) 1253-1257
78. Byrd J.C., Peterson B.L., Gabrilove J., et al. Treatment of relapsed chronic lymphocytic leukemia by 72-h continuous infusion or 1-h bolus infusion of flavopiridol: results from cancer and leukemia group B study 19,805. Clin Cancer Res 11 (2005) 4176-4181
79. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
80. Phelps M.A., Lin T.S., Johnson A.J., et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113 (2009) 2637-2645
81. Chen R., Wierda W.G., Chubb S., et al. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113 (2009) 4637-4645
82. Pepper C., Lin T.T., Pratt G., et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112 (2008) 3807-3817
83. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
84. O'Brien S.M., Claxton D.F., Crump M., et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113 (2009) 299-305
85. Wilson WH, Czuczman MS, LaCasce AS et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies [abstract]. J Clin Oncol (ASCO Annual Meeting Abstracts) 2008;28: Abstract 8511.
86. Roberts AW, Brown J, Seymour JF et al. An ongoing phase 1 study of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed or refractory chronic lymphocytic leukaemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 3177.
87. Raval A., Byrd J.C., and Plass C. Epigenetics in chronic lymphocytic leukemia. Semin Oncol 33 (2006) 157-166
88. Delgado J. Novel epigenetic targets in lymphoproliferative disorders. Curr Cancer Drug Targets 8 (2008) 378-391
89. Byrd J.C., Marcucci G., Parthun M.R., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
90. Inoue S., Walewska R., Dyer M.J., and Cohen G.M. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 22 (2008) 819-825